title: Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
abstract: Repeated postprandial hyperglycemia may play an important role in the development of atherosclerosis by suppressing vascular endothelial function. Although miglitol suppresses the elevation of blood glucose levels shortly after a meal more than other α-glucosidase inhibitors, the effect of 3-month repeated administration of miglitol on endothelial dysfunction is unknown. Fifty patients with type 2 diabetes and coronary artery disease were enrolled in the present study. The patients were randomly divided into 2 groups, the first treated with miglitol and the second with voglibose for 3 months. Blood chemistry (lipid and blood glucose profiles, glycosylated hemoglobin, 1,5-anhydroglucitol, serum insulin levels, and C-reactive protein) and flow-mediated dilatation were measured at the beginning and end of the trial period. Patient characteristics and blood chemistry of the 2 groups were similar at the beginning of the trial. At the end of the trial, glycosylated hemoglobin decreased in the 2 groups, but the improvements in 1,5-anhydroglucitol in the miglitol group were significantly higher than in the voglibose group. Insulin resistance index, C-reactive protein, and percentage flow-mediated dilatation were also improved in the miglitol group but not in the voglibose group. In conclusion, 3-month repeated administration of miglitol improved vascular endothelial dysfunction by strongly suppressing postprandial hyperglycemia. Miglitol may have antiatherogenic effects in patients with type 2 diabetes and coronary artery disease.
authors.affiliation: Division of Cardiovascular Medicine, Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Sumoto, Japan.
authors.forename: Takuo
authors.initials: T
authors.lastname: Emoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Sawada
authors.forename: Megumi
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kageyama
authors.forename: Daisuke
authors.initials: D
authors.lastname: Terashita
authors.forename: Taiji
authors.initials: T
authors.lastname: Mizoguchi
authors.forename: Takao
authors.initials: T
authors.lastname: Mizuguchi
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Motodi
authors.forename: Masamichi
authors.initials: M
authors.lastname: Iwasaki
authors.forename: Kazuki
authors.initials: K
authors.lastname: Taira
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okamoto
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Matsuo
authors.forename: Sushi-ku
authors.initials: SK
authors.lastname: Kim
authors.forename: Akira
authors.initials: A
authors.lastname: Takarada
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology*; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004562:Electrocardiography; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D005500:Follow-Up Studies; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; C045621:miglitol; D017485:1-Deoxynojirimycin